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LETTERS TO THE EDITOR
Response to the Article
“Pulmonary Resection
for Metastatic Gastric
Cancer” by Kemp et al.
To the Editor:
Searching the literature, Kemp et
al.1 found clinical reports on only 43
individuals who had surgical excision of
one or more pulmonary metastasis for
gastric cancer. On the basis of the data
extracted, the authors suggest that this
surgery should be considered for future
patients. A cautionary note is that 12 of
21 publications included in the review
were of single case reports; the median
number of cases per report is thus 1.
Case reports appear in journals primar-
ily because they are outside the norm
and unrepresentative of the usual course
of events.
The vital question is how would
patients such as these have fared were it
not for the metastasectomy; the authors
implicitly offer 2% survival as the com-
parator. Their source2 applies to patients
who had distant metastases at the time of
entry to the National Cancer Database
and are quite unlike those in Kemp’s
report where 33 of 34 patients were free
of any metastases at the time of gastrec-
tomy. Apparently 79% of patients with
metastatic disease from gastric cancer
present within 2 years of gastric resec-
tion, but the interval between gastrec-
tomy and metastasectomy was nearly 3
years in Kemp’s report. Of the 42 indi-
viduals where the pulmonary metastasis
count is provided, 34 (81%) had a single
metastasis, which is not the typical pat-
tern of metastatic disease. Is it likely that
these very few atypical cases reported
over more than 30 years, 41 of 43 from
Japan, inform practice in a disease that
kills 10,000 a year in the United States?
Parallels are drawn with pulmo-
nary metastasectomy for colorectal can-
cer.1 The conclusion of a 2010 system-
atic review reads “outcomes exceed
those normally associated with meta-
static colorectal cancer. It is this percep-
tion that has encouraged surgeons and
caused the practice to grow.”3 This is a
more tentative conclusion than Kemp et
al. suggest. Five-year survival after pul-
monary metastasectomy in colorectal
cancer has been consistently of the order
of 40% over 40 years.4 Is this a conse-
quence of surgery or selection? The
proposition put in 1980 is unresolved
after 30 years.5 To test the hypothesis,
data on Dukes stage and “disease-free
interval” from American and Japanese
reports of 144 and 159 patients6,7 were
used to construct a model among pa-
tients matched for these factors in the
Thames Cancer Registry. The model
predicted similar survival to that ob-
served, making selection the likely de-
terminant.8 (A more readily accessible
summary account is in the article by
Utley and Treasure in the journal.)9
The practice of metastasectomy is
extremely variable and increasing10 and
is without a secure evidence base.11
There is sufficient doubt about the value
of pulmonary metastasectomy for colo-
rectal cancer for a multicenter, random-
ized, controlled trial to have been set
up.12,13 What is seen in colorectal cancer
might also apply in gastric cancer, but
given the doubts about the present evi-
dence, it would be prudent to not extrap-
olate to gastric carcinoma but to seek
better evidence.
Tom Treasure, MD
Clinical Operational Research Unit (CORU)
Department of Mathematics
University College London
London, United Kingdom
Fergus Macbeth, FRCP
National Institute for Health and Clinical
Excellence (NICE)
London, United Kingdom
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In Response:
I enjoyed reading the authors’ com-
ments. At the time of writing the original
article, we found ourselves asking the ex-
act same questions. We completely agree
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with the comments made. However, we
have several important remarks that will
shed light on our intentions and conclu-
sions. First, we hypothesized that surgery
is underused in metastatic gastric cancer
and in solid-organ cancers in general. Sec-
ond, we investigated the reported data on
metastatic gastric cancer to the lung, liver,
and peritoneum.1 The question that we
asked is: Are there reported patients with
metastatic gastric cancer to these organs
that benefited from surgery and if there,
what characterize them?
Clearly, these questions cannot be
answer by such an investigation, but they
might shed light in broad strokes regard-
ing the characteristics of such patients.
Importantly, investigations of such nature
are intended as hypothesis-generating
tools, and as such that was the intention
of our article.2 As a result and because
of the need to answer such question in a
scientific manner, we designed a prospec-
tive randomized trial based on the findings
by Kemp et al.2 We designed a prospec-
tive randomized trial: the GYMSSA trial,
comparing gastrectomy plus metasta-
sectomy (lung and liver resections and
peritoneal HIPEC and CRS) versus
chemotherapy alone (ClinicalTrials.gov
ID. NCT00941655).3 Currently, the trial
is open and accruing actively.
We agree with the authors that
studies of such nature should be inter-
preted with caution. These are all retro-
spective reports of unusual cases. There
are several biases inherent in such re-
ports such as publication bias and selec-
tion bias to name a few. These types of
publications cannot answer the question
how patients such as these would have
fared were it not for the metastasectomy
(see previous paragraphs). Comparing
these patients with historical controls is
the best that one can do but the astute
reader understands that these patients
were highly selected. Thus, one of the
factors that differ between our patients
and comparable patients from the Na-
tional Cancer Data Base is the disease-
free interval and number of metastases,
as noted by the authors. These two fac-
tors can subsequently be factored when
one design a prospective study.
Finally, we think that the last sen-
tence written by the authors of this com-
mentary summarize the important issues
regarding metastasectomy: “What is seen
in colorectal cancer might also apply in
gastric cancer, but given the doubts about
the present evidence, it would be prudent
to not extrapolate to gastric carcinoma
but to seek better evidence.” Therefore
and in conclusion, in the field of meta-
static solid-organ cancers, one should
not approach patients with completely
fatalistic approach. Still and after 200
years, the only chance to cure stage IV
solid cancer is surgery (with few excep-
tions). Some, very selected, group of
patients survive longer after metastasec-
tomy. It is not completely understood
whether the selection process or surgery
or both are the reasons for our impres-
sion that this approach results in longer
survival. Also, we could not agree more
with the authors of the commentary that
we should seek better evidence and that
we are actively perusing by running the
GYMSSA Trail (ClinicalTrials.gov ID.
NCT00941655).
Itzhak Avital, MD
Surgery Branch
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, Maryland
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